Marginal group means after treatment (averaged across sites and midtreatment/end-of-treatment assessment points), adjusted for baseline values, are presented in
+Figure 2 for each outcome measure. The treatment group effect was significant for frequency of social activities (Independent Living Skills Survey) (F=6.96, df=1, 68, p=0.02, η
2=0.08), cognitive insight (Beck Cognitive Insight Scale) (F=9.91, df=1, 71, p=0.002, η
2=0.12), and mastery of cognitive behavioral social skills training skills (Comprehensive Module Test) (F=34.78, df=1, 71, p<0.001, η
2=0.33). When only engaged patients with complete data were included (on-protocol analysis), all of these treatment group effects were significant, and the effect sizes were comparable (Independent Living Skills Survey, η
2=0.05; Beck Cognitive Insight Scale, η
2=0.11; Comprehensive Module Test, η
2=0.29). The treatment group effect was not significant for skill at performing basic everyday functioning activities (UCSD Performance-Based Skills Assessment) (F=3.92, df=1, 68, p=0.052, η
2=0.05) or for any symptom measured with the Positive and Negative Syndrome Scale (positive symptoms: F=2.38, df=1, 71, p=0.13, η
2=0.03; negative symptoms: F=0.43, df=1, 71, p=0.52, η
2=0.01; total: F=1.28, df=1, 71, p=0.27, η
2=0.02) or Hamilton depression scale (F=0.84, df=1, 71, p=0.37, η
2=0.01). Psychiatric hospitalizations between baseline and the end of treatment were uncommon: two participants in treatment as usual were hospitalized (both for suicidal ideation), as were two receiving combined treatment (one for suicidal ideation and one for agitation/paranoia after clozapine was discontinued for medical reasons).